Improving the safety of whole blood-derived transfusion products with a riboflavinbased pathogen reduction technology

Blood Transfusion

Volumn 15, Issue 4, 2017, Pages 357-364

  Yonemura, Susan ^a   Doane, Suzann ^a   Keil, Shawn ^a   Goodrich, Raymond ^a,b   Pidcoke, Heather ^a   Cardoso, Marcia ^c  

^a Terumo BCT   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c Terumo BCT Europe NV   (Belgium)

Author keywords

Blood safety; Bloodborne pathogens; Emerging infectious diseases; Transfusion medicine

Indexed keywords

RIBOFLAVIN;

BLOOD; BLOOD COMPONENT; BLOOD SAFETY; BLOOD TRANSFUSION; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); ERYTHROCYTE; FEASIBILITY STUDY; HISTORY; HUMAN; ISOTOPE LABELING; LEUKOCYTE; LEUKOCYTE ACTIVATION; NONHUMAN; PATHOGEN REDUCTION SYSTEM; PRECLINICAL STUDY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; TOXICOLOGY; ULTRAVIOLET RADIATION; DISINFECTION; PLASMA; PROCEDURES; THROMBOCYTE; THROMBOCYTE TRANSFUSION;

BLOOD PLATELETS; BLOOD SAFETY; DISINFECTION; HUMANS; PLASMA; PLATELET TRANSFUSION; RIBOFLAVIN;

EID: 85021819922     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2017.0320-16     Document Type: Review

References (63)

1. World Health Organization. National Blood Policy. Available from: http://www.who.int/bloodsafety/transfusion-services/nat-blood-pol/en/. Accessed on 26/10/2016.
2. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005; 19: 110-26.
3. Owusu-Ofori AK, Parry C, Bates I. Transfusion-transmitted malaria in countries where malaria is endemic: a review of the literature from sub-Saharan Africa. Clin Infect Dis 2010; 51: 1192-8.
4. Pruett CR, Vermeulen M, Zacharias P, et al. The use of rapid diagnostic tests for transfusion infectious screening in Africa: a literature review. Transfus Med Rev 2015; 29: 35-44.
5. Roberts DJ, Field S, Delaney M, Bates I. Problems and approaches for blood transfusion in the developing countries. Hematol Oncol Clin North Am 2016; 30: 477-95.
6. Stramer SL, Dodd RY. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 2013; 53: 2375-83.
7. Norman FF, Monge-Maillo B, Martínez-Pérez Á, et al. Parasitic infections in travelers and immigrants: part I protozoa. Future Microbiol 2015; 10: 69-86.
8. Semenza JC, Lindgren E, Balkanyi L, et al. Determinants and drivers of infectious disease threat events in Europe. Emerg Infect Dis 2016; 22: 581.
9. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies. Transfusion 2007; 47: 2338-47.
10. Mundt JM, Rouse L, Van den Bossche J, Goodrich RP. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014; 90: 957-64.
11. Barbara JA, Contreras M. Transfusion microbiology. Cambridge: Cambridge University Press; 2008.
12. Solheim B, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apheresis Sci 2006; 35: 83-90.
13. Tice RR, Gatehouse D, Kirkland D, Speit G. The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment. Mutat Res 2007; 630: 50-68.
14. Ciaravino V, McCullough T, Dayan A. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001; 20: 533-50.
15. Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38: 8-18.
16. Lindholm PF, Annen K, Ramsey G. Approaches to minimize infection risk in blood banking and transfusion practice. Infect Disord Drug Targets 2011; 11: 45-56.
17. Fast LD, DiLeone G, Edson CM, Purmal A. PEN110 treatment functionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to gamma irradiation. Transfusion 2002; 42: 1318-25.
18. Fast LD, DiLeone G, Edson CM, Purmal A. Inhibition of murine GVHD by PEN110 treatment. Transfusion 2002; 42: 1326-32.
19. Fast LD, Semple JW, DiLeone G, et al. Inhibition of xenogeneic GVHD by PEN110 treatment of donor human PBMNCs. Transfusion 2004; 44: 282-5.
20. Lazo A, Tassello J, Jayarama V, et al. Broad-spectrum virus reduction in red cell concentrates using INACTINE™ PEN110 chemistry. Vo x Sanguinis 2002; 83: 313-23.
21. Mather T, Takeda T, Tassello J, et al. West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation. Transfusion 2003; 43: 1029-37.
22. Zavizion B, Pereira M, de Melo Jorge M, et al. Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry. Transfusion 2004; 44: 731-8.
23. Zavizion B, Serebryanik D, Chapman J, et al. Inactivation of Gram-negative and Gram-positive bacteria in red cell concentrates using INACTINE PEN110 chemistry. Vox Sanguinis 2004; 87: 143-9.
24. Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011; 38: 33-42.
25. Mufti N, Erickson A, North A, et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38: 14-9.
26. Klein HG, Glynn SA, Ness PM, Blajchman MA. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009; 49: 1262-8.
27. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45: 1739-49.
28. Conlan MG, Stassinopoulos A, Garratty G, et al. Antibody formation to S-303-treated RBCS in the setting of chronic RBC transfusion. Blood 2004; 104: 382.
29. Brixner V, Kiessling A-H, Madlener K, et al. Clinical safety and efficacy of red blood cell components treated with the s-303 pathogen inactivation system - A randomized controlled double-blind phase 3 study in patients requiring transfusion support of acute anemia. Vox Sanguinis 2015; 109: 28.
30. Jenkins GJ, Doak SH, Johnson GE, et al. Do dose response thresholds exist for genotoxic alkylating agents? Mutagenesis 2005; 20: 389-98.
31. Goodrich RP, Doane S, Reddy HL. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38: 20-30.
32. Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008; 22: 133-53.
33. Cardoso M, Piotrowski P, Przybylska-Baluta A, et al. Passive surveillance of blood components treated with Mirasol PRT System. Blood Transfusion 2016; 14 (Suppl 1): s62.
34. Committee for Proprietary Medicinal Products. Note for Guidance on Virus Validation Studies: The Design, Contribution, and Interpretation of Studies Validating the Inactivation and Removal of Viruses. London: EMEA; 1996.
35. Tonnetti L, Thorp AM, Reddy HL, et al. Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion 2013; 53: 860-7.
36. Owusu-Ofori S, Kusi J, Owusu-Ofori A, et al. Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage. Shock 2015; 44: 33-8.
37. Tonnetti L, Thorp AM, Reddy HL, et al. Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light. Transfusion 2014; 55: 326-9.
38. Tonnetti L, Thorp AM, Reddy HL, et al. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012; 52: 409-16.
39. Keil S, Rapaport R, Young R, et al. Viral reduction of intracellular HIV using the Mirasol® System for whole blood. Vox Sanguinis 2012; 103: s144.
40. Lee J-H, Klein HG. From leukocyte reduction to leukocyte transfusion: the immunological effects of transfused leukocytes. Best Pract Res Clin Haematol 2000; 13: 585-600.
41. Fast LD, Nevola M, Tavares J, et al. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion 2013; 53: 373-81.
42. Oka M, McCormick DB. Urinary lumichrome-level catabolites of riboflavin are due to microbial and photochemical events and not rat tissue enzymatic cleavage of the ribityl chain. J. Nutr 1985; 115: 496-9.
43. Bates C. Human requirements for riboflavin. Am J Clin Nutr 1987; 46: 122-3.
44. Halwer M. The photochemistry of riboflavin and related compounds. J Am Chem Soc 1951; 73: 4870-4.
45. Kale H, Harikumar P, Kulkarni S, et al. Assessment of the genotoxic potential of riboflavin and lumiflavin: B. Effect of light. Mutat Res 1992; 298: 17-23.
46. Kindack D, Macintosh A, Lebelle M, et al. Separation, identification and determination of lumichrome in swine feed and kidney. Food Addit Contam 1991; 8: 737-48.
47. Leclerc J. Influence of thiamine, riboflavin and vitamin B6 content in food on tissue content of these vitamins in the female lactating rat and young rats. Ann Nutr Aliment 1973; 28: 11-20.
48. McCormick DB. The fate of riboflavin in the mammal. Nutr Rev 1972; 30: 75-9.
49. Rivlin RS. Riboflavin metabolism. New Engl J Med 1970; 283: 463-72.
50. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis A randomized controlled trial. Neurology 1998; 50: 466-70.
51. Sisson T. Photodegradation of riboflavin in neonates. Fed Proc 1987; 46: 1883-5.
52. Unna K, Greslin JG. Studies on the toxicity and pharmacology of riboflavin. J Pharmacol Exp Ther 1942; 76: 75-80.
53. Yurdakök M, Erdem G, Tekinalp G. Riboflavin in the treatment of neonatal hyperbilirubinemia. Turkish Journal of Pediatrics 1987; 30: 159-61.
54. Zempleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 1996; 63: 54-66.
55. Goodrich RP, Murthy KK, Doane SK, et al. Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons. Transfusion 2009; 49: 64-74.
56. Doane SK, Yonemura SS, Hovenga N, et al. evaluation of the acute toxicity of red blood cells derived from riboflavin and UV light-treated whole blood in a canine red blood cell exchange model. Transfusion 2016; 56: 193A.
57. Okoye OT, Reddy H, Wong MD, et al. Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model. Transfusion 2015; 55: 532-43.
58. Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011; 51: 1460-8.
59. Cancelas JA, Slichter SJ, Rugg N, et al. Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage. Transfusion 2017; 57; 1218-25.
60. Hervig T, Braathen H, Jaboori AA, et al. Platelet recovery and survival after whole blood treated with mirasol pathogen reduction. Transfusion 2016; 56: 3A-262A.
61. Allain J-P, Owusu-Ofori AK, Assennato SM, et al. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016; 387: 1753-61.
62. Herzig M, Fedyk CG, Rodriguez A, et al. Blood component separation of pathogen-reduced whole blood by the PRP method produces acceptable red cells, but platelet yields and function are diminished. Transfusion 2016; 56: 78A.
63. Schubert P, Culibrk B, Karwal S, et al. Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method. Transfusion 2015; 55: 815-23.